![]() |
New to the Huntington's Disease Lighthouse? |
||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HD Lighthouse Contributing Editor's Comment: Doctors Robert Ferrante and Rajiz Ratan, with multiple collaborators, are lead authors of the recent article which details neuroprotective benefits of the drug mithramycin as found in “Chemotherapy for the Brain” (November 17 Journal of Neuroscience). Their elegant long story briefly summarized: Mithramycin extended survival of the HD R6/2 mouse longer than any other agent so far described. Likewise it improved motor performance more than any other agent. And most importantly, brain changes usually present in the R6/2 mouse were so much improved they were “essentially absent”. Though the authors use “comparatively large effect” as their careful language, these combined results are much better than for any other agent so far studied.
And, though mithramycin is not an easy drug to work with, it is already FDA approved. And accordingly the authors make the argument that mithramycin should be among the top priorities for testing in patients.
Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's DiseaseSource: J Neurosci. 2004 Nov 17;24(46):10335-10342
|
Research focusing on the formation of aggregates caused by HD
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
Research related HD and it's general affect on the brain
Learn more about the clinical trial process, trials that have been conducted and those that are underway.
Research focusing on gene therapy.
Research focusing on gene transcription.
General research related to HD
Research studying the genetics of Huntington's Disease
Research studying the Immune System and it's effect on the progression of HD
Research studying the brain tissue and research related to stem cells
19 Jul 2008
The FDA approves a Phase IIB clinical trial for ACR16
Neurosearch will begin recruiting for the trial later this year. 7 Jul 2008
Encouraging results from the Phase II Dimebon trial
Dimebon was found to be safe and well tolerated and there are indications of effectiveness. 24 Mar 2008
Approved drugs found to induce autophagy
UK researchers have found promising drugs which induce autophagy, an alternate way to clear away the HD protein. 5 Jan 2008
Zoloft raises BDNF, helps the HD mice
Sertaline (Zoloft) improves symptoms, reduces brain atrophy, and prolongs survival in the R6/2 mice. 1 Jan 2008
Screening Yields a Promising Compound
High throughput screening has identified a compound which inhibits protein aggregation. Part 1 of 3. 1 Jan 2008
C2-8 Suppresses Neurodegeneration in Drosophilia
C2-8 moves another step on the research pipeline with success in a fruitfly model of HD. Part 2 of 3. 1 Jan 2008
C2-8 Slows Progression in HD Mice
R6/2 mice given C2-8 experience delayed progression of motor symptoms and reduced cell death. Part 3 of 3 4 Dec 2007
Buck Institute and Neurobiological Technologies, Inc. Partner to Develop Treatment for HD
Following promising results in mouse models, researchers at Buck Institute and NTI will work on developing FGF-2 as a drug for HD patients. 19 Nov 2007
Miraxion results look promising
One more Phase III clinical trial is needed to support a New Drug Application. 8 Nov 2007
Minocycline accelerates ALS progression
A Phase III clinical trial of 400 mg per day of minocycline accelerated disease progression in ALS patients. All Updates for Drugs and Supplements | |||||||||||||||||||||
| Disclaimer & Privacy
Policy | |
|